• Tunicamycin Workflows for ER Stress Research

  2026-09-20

  Turn Tunicamycin into a controlled N-glycosylation inhibitor workflow for mapping ER stress, immune dysfunction, and macrophage inflammation. This guide connects biochemical pathway disruption with practical RAW264.7 and splenic CD4+ T-cell assay designs, rescue experiments, and troubleshooting decisions.

• Danazol as a Precision Perturbation Tool

  2026-09-19

  Danazol and Danocrine are examined here through a model-design lens, connecting receptor pharmacology with HPG-axis assays. The article explains how a 2025 rat study supports more rigorous interpretation of steroidogenic and puberty-related endpoints.

• Ciprofloxacin–Tetracycline Antagonism at Single-Cell Scale

  2026-09-18

  This study shows that ciprofloxacin–tetracycline antagonism is driven not simply by slower population growth, but by increased survival of individual bacterial cells under combination treatment. Microfluidic single-cell measurements further link the interaction to initial growth rate, nutrient availability, and distinct SOS-response states among ciprofloxacin-exposed cells.

• Optimized hiPSC Platelet Differentiation in Focus

  2026-09-18

  This 2026 study presents an optimized differentiation scheme that increases megakaryocyte and platelet production from human induced pluripotent stem cells while shortening culture time and lowering costs. Its main contribution is the coordinated use of embryoid-body seeding, human platelet lysate, cytokine-replacing small molecules, and maturation-promoting compounds to generate functional platelets for translational research.

• Apicidin Disrupts Oocyte Quality Through HDACs

  2026-09-17

  A 2026 study identifies a mechanistic link between Apicidin exposure, defective meiotic apparatus formation, altered histone and tubulin acetylation, DNA damage, and early apoptosis in oocytes. The findings expand evaluation of Apicidin beyond somatic-cell toxicity and provide a framework for studying how environmental histone deacetylase inhibition may affect female reproductive biology.

• 8-DY547-cGMP: CA2 PNN Evidence Boundaries

  2026-09-17

  8-DY547-cGMP is listed as product SKU C3667, but the supplied dossier provides no product-specific mechanism, potency, formulation, or Alzheimer’s disease efficacy data. The cited 2025 study establishes a CA2 perineuronal-net mechanism for social-memory impairment in 5XFAD mice, not a validated action of this reagent.

• BMS-777607 Workflows for MET Signaling Research

  2026-09-16

  BMS-777607 supports controlled MET-family pathway studies across cancer metastasis models and exploratory megakaryocyte maturation assays. This guide separates validated product evidence from practical screening recommendations so researchers can optimize target engagement, platelet differentiation, and reproducible controls.

• Mubritinib–HSA Recognition: Methods and Implications

  2026-09-16

  This study combines fluorescence spectroscopy, biochemical testing, and molecular docking to define how mubritinib recognizes human serum albumin. Its evidence for static quenching, site I binding, structural perturbation, and competitive inhibition of albumin esterase-like activity provides a mechanistic basis for interpreting distribution and protein-mediated effects of this mitochondrial electron transport chain inhibitor.

• JZL184: Monoacylglycerol Lipase Inhibitor Workflows

  2026-09-15

  JZL184 provides a practical way to elevate endogenous 2-arachidonoylglycerol while probing CB1-dependent synaptic, astrocytic, pain, and behavioral pathways. This guide translates MAGL inhibition into cell, slice, and traumatic brain injury workflows, with formulation controls and troubleshooting steps that help separate mechanism from CB1-related behavioral confounds.

• Dihydrotestosterone DHT: Practical Research Workflows

  2026-09-15

  Dihydrotestosterone enables controlled interrogation of androgen receptor signaling, EGFR/ERBB2 crosstalk, and muscle-protection phenotypes. This workflow-centered guide connects cell-based dose response, ALS-model considerations, and a carefully bounded comparison with nutrient-restricted SSC meiosis research.

• TDG, ATF4, and mTORC1 in Cell Fate

  2026-09-14

  This preprint identifies TDG as an active coordinator of ATF4-dependent transcription during retinoic acid-induced neural fate acquisition, linking promoter chromatin organization to mTORC1 activity. Its multi-omic design provides a framework for studying how DNA demethylation machinery, stress-responsive transcription, and metabolic signaling jointly stabilize differentiated cell states.

• RNA Pol II Inhibition and Apoptotic Signaling

  2026-09-14

  Harper et al. show that RNA Pol II inhibition kills cells through an active apoptotic response triggered by loss of hypophosphorylated RNA Pol IIA, rather than through transcriptional collapse alone. The findings define the Pol II degradation-dependent apoptotic response and provide a framework for interpreting transcription-targeting drugs and designing complementary cell-death experiments.

• GRK Control of M1 Receptor Biased Signaling

  2026-09-13

  The reference study uses BRET-based interaction profiling to show that GRK subtype behavior helps determine whether M1 muscarinic receptor signaling favors G proteins or β-arrestin 2. Its analysis positions BQCA as a mechanistically informative M1 allosteric modulator and provides a framework for studying acetylcholine receptor signaling relevant to cognitive function modulation and Alzheimer’s disease research.

• BMS-777607: A Decision Framework for MET Studies

  2026-09-12

  BMS-777607 is a selective c-Met inhibitor for separating MET signaling pathway inhibition from small-molecule control of megakaryocyte assays. This evidence-aware guide connects cancer metastasis models with hiPSC-derived platelet research while clarifying validated findings, practical parameters, and experimental limits.

• 25-Hydroxycholesterol Reprograms TAM Immunity

  2026-09-11

  Xiao et al. identify the CH25H–25-hydroxycholesterol axis as an immunometabolic checkpoint that links lysosomal lipid sensing to AMPK–STAT6 activation in tumor-associated macrophages. Their findings show that targeting CH25H can improve T-cell surveillance and enhance anti-PD-1 efficacy, while providing a framework for separating macrophage cholesterol signaling from parallel tumor lactate-transport mechanisms.

3649 records 1/244 page Next 12345 下5页 Last page